A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination With Interferon-Alpha 2B in Patients With Advanced Renal Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-2b
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2008 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.